Lankisch P G
Department of Internal Medicine, Municipal Hospital, Lüneburg, FRG.
Digestion. 1993;54 Suppl 2:21-9. doi: 10.1159/000201099.
Exocrine pancreatic insufficiency combined with pancreatic pain and endocrine pancreatic insufficiency are the leading symptoms of chronic pancreatitis. Due to the large functional reserve capacity of the gland, decompensation, i.e. steatorrhea, does not occur before lipase excretion is reduced to < or = 10% of normal. Pancreatic enzyme substitution is indicated when fecal fat excretion exceeds a critical value (normally > 15 g/day) and/or when weight loss is present. A number of studies have dealt with the problems of gastric acid inactivation of pancreatic enzyme preparations as well as their gastric emptying nonsimultaneously with the food. For the present, it is recommended that pancreatic enzyme substitution in patients with proven exocrine pancreatic insufficiency and normal gastric acid secretion be given in multiunit, acid-protected dosages. In patients with gastric hyposecretion and in those who underwent partial or total gastrectomy, enzyme substitution should be administered as granules to enable mixing and simultaneous transport of enzymes with the chyme. The ultimate aim of further scientific and clinical research remains the total abolishment of pancreatic steatorrhea.
外分泌性胰腺功能不全合并胰腺疼痛及内分泌性胰腺功能不全是慢性胰腺炎的主要症状。由于胰腺具有较大的功能储备能力,在脂肪酶分泌降至正常的≤10%之前,不会出现失代偿,即脂肪泻。当粪便脂肪排泄超过临界值(正常情况下>15g/天)和/或出现体重减轻时,应进行胰酶替代治疗。许多研究探讨了胰酶制剂的胃酸失活问题以及它们与食物不同时的胃排空问题。目前,对于已证实存在外分泌性胰腺功能不全且胃酸分泌正常的患者,建议给予多单位、耐酸剂型的胰酶替代治疗。对于胃酸分泌减少的患者以及接受过部分或全胃切除术的患者,应将酶替代制剂制成颗粒剂给药,以便使酶与食糜混合并同时转运。进一步科学和临床研究的最终目标仍是彻底消除胰腺性脂肪泻。